Epigenetic modifiers often harbor loss-of-function mutations in lung cancer, but their tumorsuppressive roles are poorly characterized. Here we show that lung-specific loss of the gene encoding the histone methyltransferase MLL4 (alias KMT2D; a COMPASS-like enzyme), which is ranked the most highly inactivated epigenetic modifier in lung cancer, strongly promotes lung adenocarcinoma in mice. Mll4 loss upregulated tumor-promoting programs, including glycolysis. 
Introduction
Lung cancer is the leading cause of cancer death in men and women. Lung cancer patients suffer from a low overall 5-year survival rate (~18.1%). Lung cancer is often characterized by gain-of-function mutations and gene amplification of oncogenic kinases (e.g. K-RAS and EGFR)
as well as loss-of-function alterations in tumor suppressor genes (e.g. TP53 and LKB1/STK11) [1] [2] [3] . Much research for lung cancer has focused on kinase signaling pathways, leading to the development of the kinase-targeted therapies, such as EGFR mutant inhibitors and the ALK inhibitors. However, a vast majority of lung cancer patients, who are treated with the kinasetargeted therapies, later undergo tumor relapse and drug resistance 3, 4 . Recently, the use of immune checkpoint inhibitors (e.g., anti-PD1 and anti-PD-L1) has provided significant survival benefit for lung cancer patients with high PD-L1. However, the overall survival rate of lung cancer patients still remains low 5, 6 . Moreover, a majority of lung cancer patients do not have a welldefined drug target 6, 7 . For these reasons, there is a great need for a new mechanistic understanding of lung cancer to be used for a therapeutic approach for lung cancer treatment.
Epigenetic alterations, which represent heritable aberrations in gene expression or cellular phenotype without alterations of DNA sequences, have emerged as a major type of cancer-driving events 8 . Covalent modifications of DNA and histones play a key role in epigenetic regulation of gene expression and include DNA methylation, histone acetylation, and histone methylation. Interestingly, histone methylation, which can occur at lysine and arginine residues in histones, is linked to either gene activation or silencing, depending on the methylation residues within histones 9 . Notably, histone methylation modifiers and other epigenetic modifiers are often mutated in lung tumors, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) responsible for 40%-50% and 25%-30% of lung cancer, respectively 1, 2, [10] [11] [12] . In fact, a substantial portion of such mutations results in the loss-of-function, suggesting tumor-suppressive functions of epigenetic modifiers. However, their tumor-suppressive roles in lung cancer are largely unknown. In the present study, our results show that the histone methyltransferase MLL4 (a COMPASS-like enzyme 13 ; also called KMT2D, MLL2, and ALR), which is ranked the most highly inactivated epigenetic modifier in lung tumors, is a key lung tumor suppressor against LUAD. Our findings uncover the molecular mechanism by which the epigenetic modifier MLL4 suppresses LUAD and suggest a mechanism-based therapeutic strategy for treatment of LUAD bearing low MLL4 levels or MLL4's loss-of-function mutations.
Results

Lung-specific loss of Mll4 strongly promotes K-Ras
G12D
-induced LUAD in mice
To search an epigenetic modifier with tumor-suppressive function in lung cancer, we examined which epigenetic modifier highly undergoes genomic alterations related to loss-of-function mutations (i.e., truncations, missense mutations, and insertions/deletions). Our analysis of Panlung cancer data (LUAD and LUSC) in the TCGA database showed that the gene encoding MLL4 harbored such genomic alterations in about 14% of lung tumor samples ( Fig. 1a; Supplementary   Fig. S1a, b) . Although the mutation frequencies of MLL3/KMT2C (16%) were similar to that of MLL4, MLL4 was ranked higher because truncating mutations were more frequent in MLL4 than in KMT2C (Fig. 1a) . It should be noted that most of the MLL4 truncations result in loss-of-functions because the catalytic SET domain (5397-5513 aa) is located at the C-terminus of MLL4.
Interestingly, MLL4 was altered in substantial portions of both LUAD and LUSC samples ( Supplementary Fig. S2a, b) . Because these results indicate that MLL4 is a candidate lung tumor suppressor with high genomic alterations, we chose to characterize the role of MLL4 in lung cancer in subsequent analyses.
MLL4 alterations frequently co-occur with p53 and K-RAS mutations in lung cancer. For example, about 71% of MLL4 mutations co-occur with p53 alterations in lung tumors, and about 22% of MLL4 mutations coincide with K-RAS mutation in LUAD (www.cbioportal.org) (Supplementary Fig. S3a ). Therefore, we sought to determine whether lung-specific loss of Mll4 cooperates with p53 inactivation or K-Ras activation for lung tumorigenesis. We first generated several genetically engineered mouse models (GEMMs), including p53 fl/fl ;Mll4 fl/fl and K-Ras LSL-G12D ;Mll4 fl/fl (Supplementary Fig. S3b-d) . We then induced Cre-mediated deletion of loxP sites by infecting the lungs of 6-10 weeks old GEMM mice with Adeno-Cre viruses via the commonly used intra-tracheal intubation. Lung-specific single loss or co-loss of Mll4 and p53 by Adeno-Cremediated deletion neither induced any detectable tumor in mouse lungs for up to 16 months postinfection nor changed survival times of mice ( Fig. 1b,c; Supplementary Table S1 ). This may be partly because p53 loss alone rarely induces lung tumors in mice [14] [15] [16] . For K-Ras-induced lung tumorigenesis, a K-Ras LSL-G12D model (hereinafter referred to as K-Ras model) was used because it is a well-established GEMM for LUAD 17 . K-Ras activation was induced by lung-specific deletion of the LSL (loxP-STOP-loxP) cassette via Adeno-Cre virus infection, as previously described 18 .
We monitored potential tumor formation for up to 130 days post-infection at 6-8 week intervals using a micro CT-scan.
Our micro-CT and H&E data showed that lung-specific loss of Mll4 promoted K-Ras G12D -induced lung tumorigenesis (Fig. 1b, c) . Specifically, our H&E data demonstrated that a higher percentage of the pulmonary parenchyma was effaced by tumors in the K-Ras;Mll4 −/− group of mice than in the K-Ras group of mice ( Fig. 1c; Supplementary Fig. S4a, b) . Consistent with tumorigenicity enhanced by Mll4 loss, immunohistochemisty (IHC) analysis showed that levels of the cell proliferation marker Ki-67 were increased by Mll4 loss (Fig. 1d) . Similar to K-Ras lung tumors, K-Ras:Mll4 −/− lung tumors were positive for the well-known LUAD marker TTF-1 (alias NKX2.1), indicating their LUAD characteristics (Supplementary Fig. S4c ). In contrast, expression of Keratin 5 (an LUSC marker) was weak in K-Ras;Mll4 −/− similar to K-Ras tumors (Supplementary Fig. S4c ). Our survival analysis demonstrated that Mll4 loss significantly 6 decreased the survival time of mice bearing K-Ras pulmonary tumors in the lungs (Fig. 1e) .
Because these results showed that Mll4 loss accelerated LUAD's tumorigenicity, we decided to focus on understanding how lung-specific loss of Mll4 promotes LUAD. In addition, low MLL4 mRNA levels were associated with poor prognosis in LUAD but not LUSC patients ( Fig. 1f;   Supplementary Fig. S4d ).
Glycolysis program upregulated by Mll4 loss has human LUAD relevance
To understand how lung-specific loss of Mll4 promotes LUAD, we isolated tumor lesions from K-Ras;Mll4 −/− and K-Ras lungs and examined the effect of Mll4 loss on expression profiles of K-Ras tumors using RNA-seq. Our RNA-seq data confirmed Cre-mediated deletion of loxP in the Mll4 gene as RNA peaks corresponding to Exon 16-19 of the Mll4 gene were greatly reduced.
( Supplementary Fig. S5a ). Bioinformatic analyses of RNA-seq data using Gene Set Enrichment Analysis (GSEA) and DAVID tools commonly showed that glycolysis and oxidative phosphorylation pathways were upregulated by Mll4 loss (Fig. 2a-d) . Interestingly, many glycolytic genes were also enriched in MYC and mTORC1 pathways. In contrast, these two analyses did not share any common pathway that were significantly downregulated by Mll4 loss, as GSEA analysis did not indicate any significantly downregulated pathway (Supplementary Fig.   S5b ). In line with our RNA-seq results, analysis of the TCGA lung cancer database showed that glycolysis and oxidative phosphorylation were enriched in human MLL4-low/mutant LUAD samples compared with LUAD samples bearing MLL4-high levels, indicating that our KRas:Mll4 −/− tumor model mimics human MLL4-low/mutant lung tumors (Fig. 2e-2g) . Glycolytic genes include Eno1, Pgk1, Pgam1, Ldha, Gapdh, and Cdk1, whose upregulation by Mll4 loss was confirmed by quantitative RT-PCR (Fig. 2h) . In contrast, most genes for oxidative phosphorylation were weakly upregulated by Mll4 loss (Fig. 2h) . Therefore, we delved into the regulation of glycolytic genes by MLL4.
It has been shown that upregulation of glycolysis by ENO1 19 , PGK1 20 , PGAM1 21 , LDHA 22 , and GAPDH 23 promotes tumorigenesis 24 . CDK1 is a cell cycle gene 25 and increases glycolysis 26 .
Glycolytic enzymes are considered cancer-therapeutic targets 19, 27 . In line with the above mRNA expression data, IF and IHC analysis showed that ENO1, PGK1, and PGAM1 levels were increased by Mll4 loss whereas MLL4 levels were decreased (Fig. 3a-c) . Our analysis of human LUAD database showed that ENO1, PGK1, PGAM1, LDHA, and GAPDH mRNA levels anticorrelated with MLL4 mRNA levels in human LUAD samples (Fig. 3d) . Moreover, high mRNA levels of ENO1, PGK1, PGAM1, LDHA, and GAPDH were associated with poor survival in LUAD patients (Fig. 3e) . These results from analysis of human LUAD database indicate human relevance of our findings that Mll4 loss upregulates expression of glycolytic genes in mouse LUAD.
Mll4 loss globally reduces super-enhancer and enhancer signals in mouse LUAD
We and others have shown that MLL4 can catalyze mono-, di, and trimethylation at H3K4 [28] [29] [30] [31] [32] . Monomethyl H3K4 (H3K4me1), together with acetyl H3K27 (H3K27ac), marks enhancers, which spatiotemporally activate gene expression in various locations 33 . MLL4 is required for enhancer formation regulated by the H3K27 acetyltransferases CBP and p300 34, 35 . We and others have also shown that MLL4 interacts with the H3K27me3 demethylase UTX 28, 36, 37 . For these reasons, we performed ChIP-seq for H3K4me1, H3K27ac, H3K4me3, and H3K27me3 using KRas tumors and K-Ras;Mll4 −/− tumors to analyze the effect of Mll4 loss on epigenomic landscapes and chromatin states. In the ChIP-seq experiment, we also included H3K79me2 and H3K9me3, because H3K79me2 is a commonly analyzed epigenomic mark for gene transcription and H3K9me3 is widely used to study gene repression 38, 39 . Our comprehensive analysis of combinatorial patterns of the 6 histone modifications using the analysis tool ChromHMM 40 Transcribed enhancer/State 7 to H3K4me1-low/State 5 ( Fig. 4a,b; Supplementary Fig. S6a-d) .
Further analysis confirmed that Mll4 loss did not have any obvious effect on H3K4me3 and H3K27me3 signals (Supplementary Fig. S7a-f ). In line with these results, Western blot, IHC, and IF analyses showed that global levels of H3K4me1 and H3K27ac but not H3K4me3 were downregulated by Mll4 loss (Supplementary Fig. S8a,b) . These results indicate that Mll4 loss highly and negatively impacts enhancer states.
It has been documented that enhancers can be categorized into super-enhancers and typical enhancers 41 . Super-enhancers are characterized by clusters of enhancers that are much larger than typical enhancers with a median size of 0.7-1.3 kb and highly activate gene expression 41, 42 . Average super-enhancer signals were broader than average typical enhancer signals ( Supplementary Fig. S9a,b) . Interestingly, Mll4 loss strongly decreased average H3K4me1 and H3K27ac levels in super-enhancers and to a lesser extent typical enhancers ( Fig. 4c-f 43, 44 , POMHEX (a new enolase inhibitor) a , koningic acid (KA, a selective inhibitor of GAPDH) 45 , Lonidamine (a hexokinase and mitochondrial respiration inhibitor and clinical trial phase II) 46 , and Dinaciclib (an inhibitor of CDK1 and CDK2/5/9 and clinical trial phase III) 47, 48 . To increase histone acetylation via HDAC inhibition, we used AR-42 (Clinical trial phase I) and FDA-approved SAHA/Vorinostat 49, 50 . We compared the inhibitory effects of these inhibitors on cell-proliferative abilities between human LUAD cell lines with wild type MLL4 (A549, H1792, H1437, H23, and H358) and those bearing MLL4's truncating mutations (i.e., H1568 with nonsense at E758, DV-90 with the truncating mutation P2118fs, and CORL105 with the truncating mutation R2188fs) (Supplementary Table S2 (Fig. 5g, h ). In addition, we compared the inhibitory effect of 2-DG on tumorigenic growth between H1568 cells harboring a MLL4 truncation and H358 cells harboring wild type MLL4 in a mouse xenograft model. Notably, 2-DG (500 mg/kg per day) preferentially inhibited tumorigenicity of H1568 cells compared with H358 cells (Fig. 5i-k ).
MLL4 is required for the activity of the Per2 super-enhancer, and Per2 represses glycolytic genes
Because MLL4 is a transcriptional co-activator, Mll4 loss may not directly upregulate tumor-promoting glycolysis program. Thus, we hypothesized that glycolysis program upregulated by Mll4 loss may be repressed by a tumor-suppressive, transcription-repressive regulator encoded by an MLL4-activated gene (i.e., a gene downregulated by Mll4 loss). To identify such tumor-suppressive, transcription-repressive regulator, we first searched the overlapping genes between genes downregulated by Mll4 loss (n = 522) and genes associated with significant decreases in H3K27ac levels (n = 3751), because Mll4 loss strongly downregulated the enhancer mark H3K27ac to decrease gene expression ( Fig. 6a and Supplementary Fig. S11a ). To further reduce the list for such regulator, we then incorporated human lung cancer aspects into our analysis. Specifically, we examined which Mll4-loss-downregulated genes correlate with MLL4 mRNA levels in more than 0.3 of the correlation coefficient value (r) in human LUAD samples in the TCGA database. This analysis resulted in 14 overlapping genes ( Supplementary Fig.   S11b ,c). Of these 14 genes, expression levels of five genes were lower in LUAD tumors than in adjacent normal tissues, and their low levels correlated with poor prognosis in lung cancer patients ( Fig. 6b-d; Supplementary Fig. S12a-e) . Interestingly, these genes were occupied by wide H3K27ac and H3K4me1 signals that were decreased by Mll4 loss ( Fig. 6e; Supplementary   Fig. S13a-d) .
Of the five genes, the circadian transcriptional repressor gene Per2 was particularly interesting by the following reasons: 1) Per2 loss in mouse lung promotes lung tumorigenesis 51 ;
2) Per2 loss increased glucose metabolism, implicating a role for Per2 in regulating glycolysis 51 ; and 3) disruption of circadian rhythm increases tumorigenicity 52, 53 . As mentioned above, Mll4 loss decreased Per2 expression levels ( Fig. 6f) and Per2 mRNA levels significantly correlated with MLL4 mRNA levels (Fig. 6g) . Interestingly, Per2 was occupied by a large cluster of H3K4me1 and H3K27ac peaks that are indicative of a super-enhancer (Fig. 6e,h) . In enhancer regions, RNAs called enhancer RNAs (eRNAs) are bidirectionally transcribed by RNA Polymerase II 54 .
Enhancer activities can be assessed by eRNA levels 54 . Therefore, we measured the effect of Mll4 loss on eRNA levels in the Per2-associated super-enhancer. Mll4 loss decreased eRNA levels in the super-enhancer region, suggesting that Mll4 loss reduces the activity of the Per2 super-enhancer (Fig. 6i) .
To assess whether Per2 represses glycolytic genes that are upregulated by Mll4 loss, we used the mouse K-Ras LUAD line LKR10. We first examined whether MLL4 knockdown in LKR10 cells recapitulates the effect of Mll4 loss on glycolytic genes in K-Ras tumors. In fact, MLL4
knockdown in LKR10 cells upregulated expression levels of several glycolytic genes (e.g., Eno1, Pgk1, Pgam1, Ldha, Gapdh, and Cdk1) while downregulating Per2 expression (Fig. 7a) . In line with this, MLL4 knockdown increased glucose uptake and lactate excretion (Fig. 7b,c) . We then examined the effect of Per2 knockdown and Per2 overexpression on expression of these glycolytic genes in LKR10 cells. Per2 knockdown increased expression levels of Eno1, Pgk1, Pgam1, Ldha, Gapdh, and Cdk1 genes, whereas Per2 overexpression decreased their expression levels (Fig. 7d,e) . Per2 expression levels anti-correlated with expression of several glycolytic genes (ENO1, PGK1, PGAM1, LDHA, and CDK1) in LUAD samples in the TCGA database (Fig. 7f) . Finally, we examined the effect of ectopic expression of Per2 on the spheroid growth of LKR10 cells that is increased by MLL4 depletion in the 3D culture system. Per2 reexpression decreased the spheroid growth of MLL4-depleted LKR10 cells (Fig. 7g) . These results indicate that tumor-suppressive function of MLL4 is dependent, at least in part, on the upregulation of Per2 expression by MLL4.
Discussion
It has been reported that MLL4 is required for the formation of acute myeloid leukemia by the MLL-AF9 oncogene 55 . In contrast, results reported here showed that lung-specific deletion of 
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The circadian rhythm transcriptional repressor Per2 plays an important role in tumor suppression 52, 53 
Methods
Methods, including experimental procedures and any associated accession numbers and references, are available as supplementary information.
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